T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors

• Main Authors: Virodini Merinda, -, Gatot Soegiarto, -, Laksmi Wulandari, -
• Format: Article PeerReviewed
• Language: English; English; English; English; English
• Published: Wolters Kluwer Medknow Publications 2019
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: https://repository.unair.ac.id/118318/1/Karil%20Artikel%209.pdf; https://repository.unair.ac.id/118318/2/Artikel%209.pdf; https://repository.unair.ac.id/118318/3/Turnitin%20Artikel%209.pdf; https://repository.unair.ac.id/118318/6/1.%20Karil_3.pdf; https://repository.unair.ac.id/118318/7/4.%20koresponden_3.pdf; https://repository.unair.ac.id/118318/; https://journals.lww.com/lungindia/Fulltext/2020/37010/T790M_mutations_identified_by_circulating_tumor.4.aspx; https://doi.org/ 10.4103/lungindia.lungindia_182_19
• Institution: Universitas Airlangga

Background: Plasma circulating tumor deoxyribonucleic acid (ctDNA) test is an alternative method to detect the T790M mutation. Compared to conventional tumor rebiopsy, ctDNA possesses several advantages including less invasive, faster, lower costs, and having minimal risk of complications for patien...